Description
Phenibut (beta-phenyl- gamma-aminobutyric acid, also spelled fenibut, originally known as phenigamma) is a derivative of the neurotransmitter GABA that crosses the blood-brain barrier
[1]. It was developed in Russia, and there it has been used clinically
since the 1960's for a range of purposes. Phenibut has both nootropic and anxiolytic (anxiety-reducing) properties, and it is commonly compared to diazepam (Valium), baclofen, and piracetam, and it has similarities to and differences from all of these substances.
Structurally, phenibut is similar to GABA, baclofen (p-Cl-phenibut), and β-phenylethylamine
(PEA). GABA is the primary inhibitory neurotransmitter in the brain.
The addition of the phenyl ring to GABA allows the compound to more
easily cross the blood-brain barrier, but also changes its activity
profile [1-2]. Baclofen is a drug commonly used in studies on GABA(B)
receptors, and also clinically used to treat severe spasticity of
cerebral origin [3]. PEA is a naturally occurring biogenic amine which is similar in structure to amphetamine, and like amphetamine, it is a stimulant that causes the release of dopamine, and also promotes anxiety in high enough amounts.
Phenibut is a GABA receptor agonist and also causes the release of
GABA. Similar to baclofen, phenibut is an agonist at GABA(B) receptors,
although it does have some effect on GABA(A) receptors as well [2]. It
is possible that phenibut has a higher activity at central GABA(B)
receptors than peripheral ones [4]. The role of the GABA(B) receptor is
not well-established, although research in the last seven years has
significantly increased our understanding of this receptor. The most
well-established role of GABA(B) receptors is inhibition of the release
of some neurotransmitters, and it may also serve as a negative feedback
mechanism for GABA release [5-6].
Because of the structural similarity to PEA, phenibut may share some
similarities and differences with it. When phenibut is administered
along with PEA, it antagonizes many of its effects, such as promotion
of anxiety, promotion of seizures, and hyperthermia. This has led some
to postulate that antagonism of PEA, rather than the GABA-mimetic
activity, may be the important mechanism of action for the anxiolytic
effect of phenibut [2, 7]. Phenibut also increases dopamine levels, and
it has been postulated that the structural similarity to PEA may play a
role in this effect [2].
|